ADVANCE REGISTRATION IS CLOSED.

PLEASE REGISTER ONSITE BEGINNING FRIDAY APRIL 15th.



SECOND BMP SYMPOSIUM 2011

April 16–18, 2011 | Philadelphia Marriott Downtown Hotel

featuring

Extended Clinical Applications of Recombinant Human Bone Morphogenetic Protein 2 (rhBMP-2)


ADVANCE REGISTRATION IS CLOSED

PLEASE REGISTER ON SITE BEGINNING FRIDAY APRIL 15th.


Dear Colleagues:

 

It is with great enthusiasm and pleasure that I invite you to attend the Second BMP Symposium on the Extended Clinical Applications of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) in Philadelphia.

 

The strong attendance and overwhelming success of the First BMP Symposium in San Diego last February underscores the interest and expanding applications of this remarkable biotechnology. By now, most oral and maxillofacial surgeons, periodontists, and craniofacial surgeons are aware of rhBMP-2 and its potential. This symposium will present both clinical outcome data and a “how to” technique-oriented approach to the extended applications of rhBMP-2, such as horizontal and vertical ridge augmentations, sinus augmentations, periodontal and peri-implant bone regeneration, alveolar cleft grafts, ridge split grafts, orthognathic surgery, continuity defect grafts, and rescue grafts, among others.

 

This symposium is designed to provide you with specific indications, doses, use of co-materials, and placement principles, as well as an understanding of the pitfalls to avoid, drawbacks, and a discussion of complications so that the best results in bone regeneration can be achieved. The faculty for this symposium consists of the clinicians and researchers with the most thorough scientific and clinical experience using rhBMP-2 so that everyone will receive the most up-to-date information and see case-specific examples to assess their own patients as to the applications and limitations of rhBMP-2 for their own practice.

 

I am confident that this meeting will deliver the same extraordinary learning opportunities that participants experienced during the First BMP Symposium last year. I look forward to welcomingyou to Philadelphia.

 

Sincerely,



Robert E. Marx, DDS
Program Chairman

 


ABOUT THIS COURSE

After numerous animal and human research studies that first began in 1965, the Food and Drug Administration (FDA) cleared recombinant human Bone Morphogenetic Protein-2/ACS (rhBMP-2/ACS) for two dental and oral and maxillofacial surgery indications (socket grafting and sinus augmentation) in March of 2007. In just three short years, it has met and even exceeded its clinical promise of bone regeneration without using the patient’s own bone. Extended applications into horizontal and vertical ridge augmentations, ridge splitting, implant salvage, alveolar clefts, orthognathic surgery, continuity defects, and salvaging inadequate grafts have shown that rhBMP-2/ACS can replace autogenous grafting in many other applications thereby providing a reduced complication potential and morbidity for such patients.

 

This course is designed to present the specifics of indications, techniques to be used, doses, co-materials, costs, and outcomes for these extended applications, by the researchers and clinicians with the most thorough scientific and clinical experience using rhBMP-2/ACS. This course should provide the necessary information and examples so that attendees can assess each of their own patients as to the potential use and limitations in using rhBMP-2/ACS.